US 12,404,335 B2
Compositions and methods for treatment of thyroid eye disease
Vahe Bedian, Waltham, MA (US); Peter Harwin, Dorado, PR (US); Tomas Kiselak, Dorado, PR (US); Angela She, Waltham, MA (US); Jonathan Violin, Waltham, MA (US); and Yang Zhao, Waltham, MA (US)
Assigned to Viridian Therapeutics, Inc., Waltham, MA (US)
Filed by Viridian Therapeutics, Inc., Waltham, MA (US)
Filed on Jan. 5, 2023, as Appl. No. 18/150,514.
Application 18/150,514 is a continuation of application No. 17/822,978, filed on Aug. 29, 2022, granted, now 11,548,951.
Application 17/822,978 is a continuation of application No. 17/501,362, filed on Oct. 14, 2021, abandoned.
Claims priority of provisional application 63/261,742, filed on Sep. 28, 2021.
Claims priority of provisional application 63/260,130, filed on Aug. 10, 2021.
Claims priority of provisional application 63/201,978, filed on May 21, 2021.
Claims priority of provisional application 63/091,839, filed on Oct. 14, 2020.
Prior Publication US 2023/0279122 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 27/02 (2006.01); A61K 9/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2863 (2013.01) [A61K 9/0019 (2013.01); A61P 27/02 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 9 Claims
 
1. An antibody comprising a light chain and a heavy chain, wherein:
the light chain comprises a light chain variable region comprising a LCDR1 of SEQ ID NO: 53, a LCDR2 of SEQ ID NO: 54, and a LCDR3 of SEQ ID NO: 55; and
the heavy chain comprises a heavy chain variable region comprising a HCDR1 of SEQ ID NO: 56, a HCDR2 of SEQ ID NO: 57, and a HCDR3 of SEQ ID NO: 58, and an Fc region comprising an amino acid sequence of SEQ ID NO: 89.